Metastasis suppressor gene: Basic biology and potential clinical use

Clinical Breast Cancer

Volumn 4, Issue 1, 2003, Pages 51-62

  Steeg, Patricia S ^a   Quatas, Taoufik ^a   Halverson, Douglas ^a   Palmieri, Diane ^a   Salerno, Massimiliano ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Breast cancer; Oncogenes; Targeted therapy; Tumorigenicity

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ANTINEOPLASTIC AGENT; APOPTOSIS INDUCING FACTOR; CD82 ANTIGEN; CELL NUCLEUS RECEPTOR; COLECALCIFEROL; CYCLOOXYGENASE 2 INHIBITOR; CYCLOPHOSPHAMIDE; DEXAMETHASONE; ESTROGEN; FENRETINIDE; GAMMA LINOLENIC ACID; GENE PRODUCT; HORMONE RECEPTOR; MEDROXYPROGESTERONE ACETATE; METHOTREXATE; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PREDNISOLONE; PROTEIN CRSP3; PROTEIN KISS1; PROTEIN NM23; PROTEIN RHOGD12; PROTEIN TYROSINE KINASE INHIBITOR; REGULATOR PROTEIN; RETINOIC ACID; TAMOXIFEN; THIOREDOXIN; THYROID HORMONE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANIMAL CELL; BIOCHEMISTRY; BREAST CANCER; BREAST CARCINOGENESIS; CANCER CELL; CANCER CELL CULTURE; CANCER GROWTH; CANCER LOCALIZATION; CANCER STAGING; CLINICAL TRIAL; DNA METHYLATION; DRUG POTENTIATION; EXPERIMENTAL DESIGN; GENE EXPRESSION; HIGH RISK POPULATION; HUMAN; HUMAN CELL; HYPOTHESIS; IN VITRO STUDY; IN VIVO STUDY; METASTASIS; MOLECULAR BIOLOGY; MOUSE; NONHUMAN; PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION; SUPPRESSOR GENE; UPREGULATION; ANIMAL; BREAST TUMOR; CELL DIVISION; FEMALE; GENE EXPRESSION REGULATION; GENETICS; PATHOLOGY; TUMOR SUPPRESSOR GENE;

ANIMALS; BREAST NEOPLASMS; CELL DIVISION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; HUMANS; NEOPLASM METASTASIS;

EID: 0038662614     PISSN: 15268209     EISSN: None     Source Type: Journal    
DOI: 10.3816/CBC.2003.n.012     Document Type: Review

References (156)

1. Jemal A, Murray T, Samuels A, et al. Cancer statistics, 2003. CA Cancer J Clin 2003; 53:5-26.
2. Weiss L, Grundmann E, Torhorst J, et al. Haematogenous metastatic patterns in colonic carcinoma: an analysis of 1541 necropsies. J Pathol 1986; 150:195-203.
3. Trepel M, Arap W, Pasqualini R. In vivo phage display and vascular heterogeneity: implications for targeted medicine. Curr Opin Chem Biol 2002; 6:399-404.
4. Sloan E, Anderson R. Genes involved in breast cancer metastasis to the bone. Cell Mol Life Sci 2002; 59:1491-1502.
5. Maniotis A, Folberg R, Hess A, et al. Vascular channel gformation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. Am J Pathol 1999; 155:739-752.
6. Hendrix M, Seftor E, Kirschmann D, et al. Can breast cancer cells undergo vasculogenic mimicry? Breast Cancer Res 2000; 2:417-422.
7. Sugino T, Kusakabe T, Hoshi N, et al. An invasion-independent pathway of blood-borne metastasis. A new murine mammary tumor model. Am J Pathol 2002; 160:1973-1980.
8. Weidner N. New paradigm for vessel intravasation by tumor cells. Am J Pathol 2002; 160:1937-1939.
9. Paget S. The distribution of secondary growths in cancer of the breast. Lancet 1889; 1:99-101.
10. Fidler I. The organ microenvironment and cancer metastasis. Differentiation 2002; 70:498-505.
11. Witz I. The tumour microenvironment - introduction. Seminars in Cancer Biol 2002; 12:87-88.
12. Muller A, Homey B, Soto H, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001; 410:50-56.
13. Guba M, Cernaianu G, Koehl G, et al. A primary tumor promotes dormancy of solitary tumor cells before inhibiting angiogenesis. Cancer Res 2001; 61:5575-5579.
14. Rubio N, Espna L, Fernandez Y, et al. Metastatic behavior of human breast caricnomas overexpressing the Bel-xL gene: A roldin dormancy and organospecificity. Lab Invest 2001; 81:725-734.
15. Naumov G, MacDonald I, Weinmeister P, et al. Persistence of solitary mammary carcinoma cells in a secondary site: a possible contributor to dormancy. Cancer Res 2002; 62:2162-2168.
16. Jiang WG, Martin, TA, Mansel RE. Molecular detection of micrometatasis in breast cancer. Crit Rev Oncol Hemat 2002; 43:13-31.
17. Hawes D, Neville AM, Cote RJ. Detection of occult metastasis in patients with breast cancer. Semin Surg Oncol 2001; 20:312-318.
18. Dalton W The tumor microenvironment as a determinant of drug response and resistance. Drug Resist Update 1999; 2:285-288.
19. Welch D. Technical considerations for studying cancer metastasis in vivo. Clin Exp Metastasis 1997; 15:272-306.
20. Seraj M, Samant R, Verderame M, et al. Functional evidence for a novel human breast carcinoma metastasis suppressor, BRMS1, encoded at chromosome 11q13. Cancer Res 2000; 60:2764-2769.
21. Hiraga T, Williams P, Mundy G, et al. The bisphosphonate ibandronate promotes apoptosis in MDA-MB-231 human breast cancer cells in bone metastases. Cancer Res 2001; 61:4418-4424.
22. Yoneda T, Williams P, Hiraga T, et al. A bone seeking clone exhibits different biological properties from the MDA-MB-231 parental human breast cancer cells and a brain-seeking cloe in vivo and in vitro. J Bone Miner Res 2001; 16:1486-1495.
23. Price JE, Polyzos A, Zhang RD, et al. Tumorigenicity and metastasis of human breast carcinoma cell lines in nude mice. Cancer Res 1990; 50:717-721.
24. Leone A, Flatow U, VanHoutte K, et al. Transfection of human nm23-H1 into the human MDA-MB-435 breast carcinoma cell line: Effects on tumor metastatic potential, colonization, and enzymatic activity Oncogene 1993; 8:2325-2333.
25. Pan Q, Kleer C, vanGolen K, et al. Copper deficiency induced by tetrathiomolybdate suppresses tumor growth and angiogenesis. Cancer Res 2002; 62:4854-4859.
26. Auerbach R, Akhtar N, Lewis R, et al. Angiogenesis assays: problems and pitfalls. Cancer Metastasis Rev 2000; 19:167-172.
27. Fukuda M, Ishii A, Yasutomo Y, et al. Metastatic potential of rat mammary adenocarcinoma cells associated with decreased expression of nucleoside diphosphate kinase/nm23: reduction by transfection of NDP Kinase a isoform, an nm23-H2 gene homolog. Int J Cancer 1996; 65:531-537.
28. Bhujwalla Z, Aboagye E, Gilles R, et al. Nm23-transfected MDA-MB-435 human breast carcinoma cells form tumors with altered phospholipid metabolism and pH: a 31P nuclear magnetic resonance study in vivo and in vitro. Magn Res Med 1999; 41:897-903.
29. Russell R, Geisinger K, Mehta R, et al. nm23- Relationship to the metastatic potential of breast cancerinoma cell lines, primary human xenografts and lymph node negative breast carcinoma patients. Cancer 1997; 79:1158-1165.
30. Hartsough M, Morrison D, Salerno M, et al. Nm23-H1 metastasis suppressor phosphorylation of kinase suppressor of ras (KSR), via a histidine protein kinase pathway. J Biol Chem 2002; 277:32389-32399.
31. Wagner P, Vu ND. Phosphorylation of ATP-Citrate Lyase by Nucleoside diphosphate kinase. J Biol Chem 1995; 270:21758-21764.
32. Wagner PD, Steeg PS, Vu ND. Two-component kinase like activity of nm23 correlates with its motility suppressing activity. Proc Natl Acad Sci U S A 1997; 94:9000-9005.
33. Wagner P, Vu ND. Histidine to aspartate phosphotransferase activity of nm23 protein: Phosphorylation of Aldolase C on Asp 319. Biochem J 2000; 346:623-630.
34. Freije JMP, Blay P, MacDonald NJ, et al. Site-directed mutation of nm23-H1: mutations lacking motility suppressive capacity upon transfection are deficient in histidine-dependent protein phosphotransferase pathways in vitro. J Biol Chem 1997; 272:5525-5532.
35. Miele ME, Rosa ADL, Lee JH, et al. Suppression of human melanoma metastasis following introduction of chromosome 6 is independent of NME1 (nm23). Clin Exp Metastasis 1997; 15:259-265.
36. Leone A, Flatow U, King CR, et al. Reduced tumor incidence, metastatic potential, and cytokine responsiveness of nm23-transfected melanoma cells. Cell 1991; 65:25-35.
37. Baba H, Urano T, Okada K, et al. Two isotypes of murine nm23/nucleoside diphosphate kinase, nm23-M1 and nm23-M2, are involved in metastatic suppression of a murine melanoma line. Cancer Res 1995; 55:1977-1981.
38. Parhar RS, Shi Y, Zou M, et al. Effects of cytokine mediated modulation of nm23 expression on the invasion and metastatic behavior of B16F10 melanoma cells. Int J Cancer 1995; 60:204-210.
39. Wallet V, Mutzel R, Troll H, et al. Dictyostelium Nucleoside diphosphate kinase highly homologous to nm23 and Awd proteins involved in mammalian tumor metastasis and Drosophila development. J Natl Cancer Inst 1990; 82:1199-1202.
40. Tagashira H, Hamazaki K, Tanaka N, et al. Reduced metastatic potential and c-myc overexpression of colon adenocarcinoma cells (Colon 26 line) transfected with nm23-R2 rat nucleoside diphosphate kinase a isoform. Int J Mol Med 1998; 2:65-68.
41. Otsuki Y, Tanaka M, Yoshii S, et al. Tumor metastasis suppressor nm23H1 regulates Rae GTPase by interaction with Tiam1. Proc Natl Arad Sci U S A 2001; 98:4385-4390.
42. Randazzo PA, Northup JK, Kahn RA. Regulatory GTP binding proteins (ARF, Gt and RAS) are not activated directly by nucleoside diphosphate kinase. J Biol Chem 1992; 267:18182-18189.
43. Engel M, Seifert M, Theisinger B, et al. Glyceraldehyde-3-phosphate dehydrogenase and nm23-H1/Nucleoside diphosphate kinase A: two old enzymes combine for the novel nm23 protein phosphotransferase function. J Biol Chem 1998; 273:20058-20065.
44. Nosaka K, Kawahara M, Masuda M, et al. Association of nucleoside diphosphate kinase nm23-H2 with human telomeres. Biochem Biophys Res Commun 1998; 243:342-348.
45. Zhu J, Tseng YH, Kantor J, et al. Interaction of the Ras-related protein associated with diabetes Rad and the putative tumor metastasis suppressor NM23 provides a novel mechanism of GTPase regulation. Proc Natl Acad Sci U S A 1999; 96:14911-14918.
46. Tseng Y, Vincent D, Zhu J, et al. Regulation of growth and tumorigenicity of breast cancer cells by the low molecular weight GTPase Rad and nm23. Cancer Res 2001; 61:2071-2079.
47. Subramanian C, Cotter M, Robertson E. Epstein-Barr virus nuclear protein EBNA-3C interacts with the human metastatic suppressor nm23-H1: a molecular link to cancer metastasis. Nat Med 2001; 7:350-355.
48. Otero A. Copurification of vimentin, energy metabolism ensymes and a MER5 homolog with nucleoside diphosphate kinase. Identification of tissue-specific interactions. J Biol Chem 1997; 272:14690-14694.
49. Roymans D, Willems R, Vissenberg K, et al. Nucleoside diphosphate kinase b (nm23-R1/NDPKb) is associated with intermediate filaments and becomes upregulated upon cAMP-induced differentiation of rat C6 glioma. Exp Cell Res 2000; 261:127-138.
50. Pinon V, Millot G, Munier A, et al. Cytoskeletal association of the A and B nucleoside diphosphate kinases of interphasic but not mitotic human carcinoma cell lines: specific nuclear localization of the B subunit. Exp Cell Res 1999; 246:355-367.
51. Fournier H, Dupe-Manet S, Bouvard D, et al. Integrin cytoplasmic domain-associated protein 1a (ICAP-1a) interacts directly with the metastasis suppressor nm23-H2, and both proteins are targeted to newly formed cell adhesion sites upon integrin engagement. J Biol Chem 2002; 277:20895-20902.
52. Kimura N, Shimada N. Evidence for complex formation between GTP binding protein (Gs) and membrane-associated nucleoside diphosphate kinase. Biochem Biophys Res Commun 1990; 168:99-106.
53. Otero A, Doyle M, Hartsough M, et al. Wild type nm23-H1, but not the S120G mutant, suppresses desensitization of muscarinic potassium currents expressed in breast carcinoma cells. Biochim Biophys Acta 1999; 1449:157-168.
54. Miyazaki H, Fukuda M, Ishijima Y, et al. Overexpression of nm23-H2/NDP Kinase B in a human oral squamous cell carcinoma cell line results in reduced metastasis, differentiated phenotype in the metastatic site, and growth factor-independent proliferative activity in culture. Clin Cancer Res 1999; 5:4301-4307.
55. Postel EH, Berberich SJ, Flint SJ, et al. Human c-myc transcription factor PuF identified as nm23-H2 nucleoside diphosphate kinase, a candidate suppressor of tumor metastasis. Science 1993; 261:478-480.
56. Michelotti E, Sanford S, Freije J, et al. Nm23/PuF does not directly stimulate transcription through the CT element in vivo. J Biol Chem 1997; 272:22526-22530.
57. Ma D, Xing Z, Liu B, et al. Nm23-H1 and nm23-H2 repress transcriptional activities of nuclease-hypersensitive elements in the platelet-derived growth factor A promoter. J Biol Chem 2002; 277:1560-1567.
58. Hildebrandt M, Lacombe M, Mesnildrey S, et al. A human NDP-Knase-B specifically binds single-stranded poly-pyrimidine sequences. Nucl Acids Res 1995; 23:3858-3864.
59. Postel E. Cleavage of DNA by human NM23-H2/Nucleoside diphosphate kinase involves formation of a covalent protein-DNA complex. J Biol Chem 1999; 274:22821-22829.
60. Yang X, Wei L, Tang C, et al. Overexpression of KAI1 supprresses in vitro invasiveness and in vivo metastasis in breast cancer cells. Cancer Res 2001; 61:5284-5288.
61. Bienstock R, Barrett J. Kai1, a prostate metastais suppressor: Prediction of solvated structure and interactions with binding partners, integrins, cadherins, and cell-surface receptor proteins. Mol Carcinog 2001; 32:139-153.
62. Dong J, Lamb P, Rinker-Schaeffer C, et al. Kai1, a metastasis suppressor gene for prostate cancer on human chromosome 11p11.2. Science 1995; 268:884-886.
63. Odintsova E, Sugiura T, Berditchevski F. Attenuation of EGF receptor signaling by a metastasis supressor, the tetraspanin CD82/KAI-1. Curr Biol 2000; 10:1009-1012.
64. Shevde L, Samant R, Goldberg S, et al. Suppression of human melanoma metastasis by the metastasis suppressor gene, BRMS1. Exp Cell Res 2002; 273:229-239.
65. Saunders M, Seraj M, Li Z, et al. Breast cancer metastastic potential correlates with a breakdown in homospecific and heterospecific gap junctionalintercellular communication. Cancer Res 2001; 61:1765-1767.
66. Lee J, Welch D. Suppression of metastasis in human breast carcinoma MDA-MB-435 cells after transfection with the metastasis suppressor gene, Kiss-1. Cancer Res 1997; 57:2384-2387.
67. Kotani M, Detheux M, Vandenbogaerde A, et al. The metastasis suppressor gene KiSS-1 encodes kisspeptins, the natural ligands of the orphan G protein-coupled receptor GRP54. J Biol Chem 2001; 276:34631-34636.
68. Muir A, Chamerbalin L, Elshourbagy N, et al. AXOR12, a novel human G protein-coupled receptor, activated by the peptide Kiss-1. J Biol Chem 2001; 276:28969-28975.
69. Ohtaki T, Shintani Y, Honda S, et al. Metastasis suppressor Kiss-1 encodes a peptide ligand of a G-protein-coupled receptor. Nature 2001; 411:613-617.
70. Lee J, Miele M, Hicks D, et al. Kiss-1, a novel human malignant melanoma metastasis-suppressor gene. J Natl Cancer Inst 1996; 88:1731-1737.
71. Yoshida B, Dubauskas Z, Chekmareva M, et al. Mitogen-activated protein kinase 4/stress-activated protein/Erk kinase 1 (MKK4/SEK1), a prostate cancer metastasis suppressor gene encoded by human chromosome 17. Cancer Res 1999; 59:5483-5487.
72. Yamada S, Hickson J, Hrobowski Y, et al. Mitogen-activated protein kinase kinase 4 (MKK4) acts as a metastasis suppressor gene in human ovarian carcinoma. Cancer Res 2002; 62:6717-6723.
73. Gildea J, Seraj M, Oxford G, et al. RhoGD12 is an invasion and metastasis suppressor gene in human cancer. Cancer Res 2002; 62:6418-6423.
74. Goldberg S, Miele M, Hatta N, et al. Melanoma metastasis suppression by chromosome 6: evidence for a pathway regulated by CRSR3 and TXNIP. Cancer Res 2003; 63:432-440.
75. Ryu S, Zhou S, Ladurner A, et al. The transcriptional cofactor complex CRSP is required for activity of the enhancer-binding protein Sp1. Nature 1999; 397:446-450.
76. Junn E, Han S, Im J, et al. Vitamin D3 up-regulated protein 1 mediates oxidative stress via suppressing the thioredoxin function. J Immunol 2000; 164:6287-6295.
77. Okabe-Kado J, Kasukabe T, Baba H, et al. Inhibitory actions of nm23 proteins on induction of erythroid differentiation of human leukemia cells. Biochim Biophys Acta 1995; 1267:101-106.
78. Shinohara T, Nishimura N, Hanibuchi M, et al. Transduction of KAI1/CD82 cDNA promotes hematogenous spread of human lung-cancer cells in natural killer cell-depleted SCID mice. Int J Cancer 2001; 94:16-23.
79. Luo J, Lubaroff D, Hendrix M. Suppression of prostate cancer invasive potential and matrix metalloproteinase activity by E-cadherin transfection. Cancer Res 1999; 59:3552-3556.
80. Sager R, Sheng S, Pemberton P et al. Maspin - a tumor suppressing serpin. Adv Exp Med Oncol 1997; 425:77-88.
81. Shih JY, Yang SC, Hong TM, et al. Collapsin response mediator protein-1 and the invasion and metastasis of cancer cells. J Natl Cancer Inst 2001; 93:1392-1400.
82. Kirschmann D, Lininger R, Gardner L, et al. Down-regulation of HP1 (Hs alpha) expression is associated with the metastastic phenotype in breast cancer. Cancer Res 2000; 60:3359-3363.
83. Xia W, Unger P, Miller L, et al. The Src-suppressed C kinase substrate, SSeCKS, is a potential metastasis inhibitor in prostate cancer. Cancer Res 2001; 61:5644-5651.
84. Steeg PS, Bevilacqua G, Kopper L, et al. Evidence for a novel gene associated with low tumor metastatic potential. J Natl Cancer Inst 1988; 80:200-204.
85. Dearolf C, Tripoulas N, Biggs J, et al. Molecular consequences of awdb3, A cell autonomous lethal mutation of Drosophila induced by hybrid dysgenesis. Dev Biol 1988; 129:169-178.
86. Dearolf C, Hersperger E, Shearn A. Developmental consequences of awdb3, a cell autonomous lethal mutation of Drosophila induced by hybrid dysgenesis. Dev Biol 1988; 129:159-168.
87. Lacombe ML, Milon L, Munier A, et al. The human nm23/nucleoside diphosphate kinases. J Bioenerg Biomembr 2000; 32:247-258.
88. Hartsough M, Steeg P. Nm23/nucleoside diphosphate kinase in human cancers. J Bioenerg Biomembr 2000; 32:301-308.
89. Kantor JD, McCormick B, Steeg PS, et al. Inhibition of cell motility after nm23 transfection of human and murine tumor cells. Cancer Res 1993; 53:1971-1973.
90. MacDonald N, Freije J, Stracke M, et al. Site directed mutagenesis of nm23-H1: mutation of proline 96 or serine 120 abrogates its motility inhibitory activity upon transfection into human breast carcinoma cells. J Biol Chem 1996; 271:25107-25116.
91. Bemis L, Schedin P Reproductive state of rat mammary gland stroma modulates human breast cancer cell migration and invasion. Cancer Res 2000; 60:3414-3418.
92. Leone A, Seeger RC, Hong CM, et al. Evidence for nm23 RNA overexpression, DNA amplification and mutation in aggressive childhood neuroblastomas. Oncogene 1993; 8:855-865.
93. Howlett AR, Petersen OW, Steeg PS, et al. A novel function for nm23: overexpression in human breast carcinoma cells leads to the formation of basement membrane and growth arrest. J Natl Cancer Inst 1994; 86:1838-1844.
94. Gervasi F, D'Agnano I, Vossio S, et al. nm23 influences proliferation and differentiation of PC12 cells in response to nerve growth factor. Cell Growth Diff 1996; 7:1689-1695.
95. Ishijima Y, Shimada N, Fukada M, et al. Overexpression of nucleoside diphosphate kinases induced neurite outgrowth and their substitution to inactive forms leads to suppression of nerve growth factor- and dibutryl cAMP-induced effects in PC12D cells. FEBS Lett 1999; 445:155-159.
96. Amendola R, Martinez R, Negroni A, et al. DR-nm23 gene expression in neuroblastoma cells: Relationship to integrin expression, adhesion characteristics, and differentiation. J Natl Cancer Inst 1997; 89:1300-1310.
97. Salerno M, Ouatas T, Palmieri D, et al. Inhibition of signal transduction by the nm23 metastatsis suppressor: possible mechanisms. Clin Exp Metastasis 2003; 20:3-10.
98. Bienstock R, Barrett J. KAI1, a prostate metastasis suppressor: prediction of solvated structure and interactions with binding partners, integrins, caherins and cell-surface receptor proteins. Mol Carcinog 2001; 32:139-153.
99. Yang X, Wei L, Tang C, et al. KAI1 protein is down-regulated during the progression of human breast cancer. Clin Cancer Res 2000; 6:3424-3429.
100. Samant R, Saraj M, Saunders M, et al. Analysis of mechanisms underlying BRMS1 suppression of metastasis. Clin Exp Metastasis 2001; 18:683-693.
101. Kim H, Griend DV, Yang X, et al. Mitogen-activated protein kinase kinase 4 metastasis suppressor gene expression is inversely related to histological pattern in advancing human prostatic cancers. Cancer Res 2001; 61:2833-2837.
102. Robinson V, Hickson J, Vander Griend D, et al. MKK4 and metastasis suppression: a marriage of signal transduction and metastasis research. Clin Exp Metastasis 2002; 20:25-30.
103. Johnson J, Decker S, Zaharevitz D, et al. Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials. Br J Cancer 2001; 84:1424-1431.
104. Elder D, Halton D, Playle L, et al. The MEK/ERK pathway mediated COX-2-selective NSAID-induced apoptosis and induced COX-2 protein expression in colorectal carcinoma cells. Int J Cancer 2002; 99:323-327.
105. Magne N, Fischel J, Dubreuil A, et al. Influence of epidermal growth factor receptor (EGFR), p53 and intrinsic MAP kinase pathway status of tumour cells on the antiproliferative effect of ZD 1839 ("Iressa"). Br J Cancer 2002; 86:1518-1523.
106. Sarker M, Ruiz-Ruiz C, Robledo G, et al. Stimulation of the mitogen-activated protein kinase pathway antagonizes TRAIL-induced apoptosis downstream of BID cleavage in human breast cancer MCF-7 cells. Oncogene 2002; 21:4323-4327.
107. MacKeigan J, Taxman D, Hunter D, et al. Inactivation of the antiapoptotic phosphatidylinositol 3-kinase-Akt pathway by the ocmbined treatment of taxol and mitogen-activated protein kinase kinase inhibition. Clin Cancer Res 2002; 8:2091-2099.
108. Orlowski R, Small G, Shi Y. Evidence that inhibition of p44/42 mitogen-activated protein kinase signaling is a factor in proteasome inhibitor-meidated apoptosis. J Biol Chem 2002; 277:27864-27871.
109. Chekmareva M, Kadkhodaian M, Hollowell C, et al. Chromosome 17-mediated dormancy of AT6.1 prostate cancer micrmetastases. Cancer Res 1998; 58:4963-4969.
110. Goldberg S, Harms J, Quon K, et al. Metastasis suppressed C8161 melanoma cells arrest in lung but fail to proliferate. Clin Exp Metastasis 1999; 17:601-607.
111. Steeg P. Metastasis suppressors alter the signal transduction of cancer cells. Nat Rev Cancer 2003; 3:55-63.
112. Cropp, C, Lidereau R, Leone A, et al. NME1 protein expression and loss of heterozygosity mutations in primary human breast tumors. J Natl Cancer Inst 1994; 86:1167-1169.
113. Chang C, Zhu XX, Thoraval D, et al. Nm23-H1 mutation in neuroblastoma. Nature 1994; 370:335-336.
114. Uzawa K, Ono K, Suzuki H, et al. High prevalence of decreased KAI1 metastasis suppressor in oral carcinogenesis. Clin Cancer Res 2002; 8:828-835.
115. Miyazaki T, Kato H, Shitara Y, et al. Mutation and expression of the metastasis suppressor gene KAI1 in esophageal squamous cell carcinoma. Cancer 2000; 89:955-962.
116. Liu F Dong J, Chen J, et al. Frequent down-regulation andlack of mutation of the KAI1 metastasis suppressor gene in epithelial ovarian carcinoma. Gynecol Oncol 2000; 78:10-15.
117. Tagawa K, Arihiro K, Takeshima Y, et al. Down-regulation of KAI1 messenger RNA expression is not associted with loss of heterozygosity of the KAI1 gene region in lung adenocarcinoma. Jpn J Cancer Res 1999; 90:970-976.
118. Yoshida H, Kijima H, Terasaki Y, et al. Heterogenous expression of nm23 gene product as a predictor of lymph nodal status in human breast cancer. Int J Oncol 1998; 13:1141-1146.
119. Betke H, Korabiowska M, Brinck U, et al. The role of nm23 in melanoma progression and its prognostic significance. Pol J Pathol 1998; 49:93-96.
120. Kumar D, Kubota H, Tabara H, et al. nm23 in the primary and metastatic sites of gastric carcinoma. Relation to AFP-producing carcinomas. Oncology 1999; 56:122-128.
121. Sarac E, Ayhan A, Ertoy D, et al. nm23 expression in carcinoma of the uterine cervix. Eur J Gynaecol Oncol 1998; 19:312-315.
122. Ohta Y, Nozawa H, Tanaka Y, et al. Increased vascular endothelial growth factor and vascular endothelial growth factor-C and decreased NM23 expression associated with microdissemination in the lymph nodes in stage I non-small cell lung cancer. J Thorac Cardiovasc Surg 2000; 119:804-813.
123. Friess H, Guo X, Tempia-Caliera A, et al. Differential expression of metastasis-associated genes in Papilla of Vater and pancreatic cancer correlates with disease stage. J Clin Oncol 2001; 19:2422-2432.
124. Takes R, Baatenburg de Jong R, Wijffels K, et al. Expression of genetic markers in lymph node metastases compared with their primary tumors in head and neck cancer. J Pathol 2001; 194:298-302.
125. Sarris M, Lee C. nm23 protein expression in colorectal carcinoma metastasis in regional lymph nodes and the liver. Eur J Surg Oncol 2001; 27:170-174.
126. Shimada M, Taguchi K, Hasegawa H, et al. Nm23-H1 expression in intrahepatic or extrahepatic metastases of hepatocellular carcinoma. Liver 1998; 18:337-342.
127. Kanitakis J, Euvrard S, Bourchany D, et al. Expression of the nm23 metastasis-suppressor gene product in skin tumors. J Cuton Pathol 1997; 24:151-156.
128. Kawakubo Y, Sato Y, Koh T, et al. Expression of nm23 protein in pulmonary adenocarcinomas: inverse correlation to tumor progression. Lung Cancer 1997; 17:103-113.
129. Tomita M, Ayabe T, Matsuzaki Y, et al. Immunohistochemical analysis of nm23-H1 gene product in node-positive lung cancer and lymph nodes. Lung Cancer 1999; 24:11-16.
130. Hsu N, Chow K, Chen W, et al. Expression of nm23 in the primary tumor and the metastatic regional lymph nodes of patients with gastric cardiac cancer. Clin Cancer Res 1999; 5:1752-1757.
131. Gunduz M, Ayhan A, Gullu I, et al. nm23 protein expression in larynx cancer and the relationship with metastasis. Eur J Cancer 1997; 33:2338-23341.
132. Lombardi D, Geradts J, Foley J, et al. Loss of KAI1 expression in the progression of colorectal cancer. Cancer Res 1999; 59:5724-5731.
133. Maurer C, Graber H, Friess H, et al. Reduced expression of the metastasis suppressor KAI1 in advanced colon cancer and its metastases. Surgery 1999; 126:869-880.
134. Verma M, Srivastava S. Epigentics in cancer: implications for early detection and prevention. Lancet Oncol 2002; 3:755-763.
135. Widschwendter M, Jones P. DNA methylation and breast carcinogenesis. Oncogene 2002; 21:5462-5482.
136. Hartsough M, Clare S, Mair M, et al. Elevation of breast carcinoma nm23-H1 metastasis suppressor gene expression and reduced motility by DNA methylation inhibition. Cancer Res 2001; 61:2320-2327.
137. Jackson P, Millar D, Kingsley E, et al. Methylation of a CpG island within the promoter region of the KAI1 metastasis suppressor gene is not responsible for down-regulation of KAI1 expressionin invasive cancers or cancer cell lines. Cancer Lett 2000; 157:169-176.
138. Sekita N, Suzuki H, Ichikawa T, et al. Epigenetic regulation of the KAI1 metastasis suppressor gene in human prostate cancer cell lines. Jpn J Cancer Res 2001; 92:947-951.
139. Liu F, Qi HL, Chen HL. Effects of all-trans retinoic acid and epidermal growth factor on the expression of nm23-H1 in human hepatocarcinoma cells. J Cancer Res Clin Oncol 2000; 126:85-90.
140. Jiang W, Redfern A, Bryce R, et al. Peroxisome proliferator activated receptor-g (PPAR-g) mediates the action of gamma linolenic acid in breast cancer cells. Prostaglandins Leukot Essent Fatty Acids 2000; 62:119-127.
141. Jiang W, Hiscox S, Bryce R, et al. The effects of n-6 polyunsaturated fatty acids on the expression of nm-23 in human cancer cells. Br J Cancer 1988; 77:731-738.
142. Ouatas T, Halverson D, Steeg P. Dexamethasone and medroxyprogesterone acetate elevate nm23-H1 metastasis suppressor expression in metastatic human breast carcinoma cells via glucocorticoid receptor-dependent, transcriptional and post-transcriptional mechanisms: new uses for old compounds. Clin Cancer Res 2003 (in press).
143. Lin K, Wang W, Wu Y, et al. Activation of antimetastatic nm23-H1 gene expression by estrogen and its a-receptor. Endocrinology 2002; 143:467-475.
144. Lin K, Shieh H, Hsu H. Negative regulation of the antimetastatic gene nm23-h1 by thyroid hormone receptors. Endocrinology 2000; 141:2540-2547.
145. Chen K, DeLuca H. Isolation and characterization of a novel cDNA from HL-60 cells treated with 1.25-dihydroxyvitamin D-3. Biochim Biophys Acta 1994; 1219:26-32.
146. Munoz S, Lopez C, Valentich M, et al. Differential modulation by dietary n-6 or n-9 unsaturated fatty acids on the development of two murine mammary gland tumors having different metastatic capabilities. Cancer Lett 1998; 126:149-155.
147. Menendez J, Ropero S, del Barbacid M, et al. Synergistic interaction between vinorelbine and gamma-linolenic acid in breast cancer cells. Breast Cancer Res Treatment 2002; 72:203-219.
148. Menendez J, Barbacid M, Montero S, et al. Effects of gamma-linolenic acid and oleic acid on paclitaxel cytotoxicity in human breast cancer cells. Eur J Cancer 2001; 37:402-413.
149. Kenny F, Pinder S, Ellis I, et al. Gamma linolenic acid with tamoxifen as primary therapy in breast cancer. Int J Cancer 2000; 85:643-648.
150. Ouatas T, Clare S, Hartsough M, et al. A cassette of mammary-specific transcription factor binding sites contributes to nm23-H1 promoter activity in human breast carcinoma cell lines. Clin Exp Metastasis 2002; 19:35-42.
151. Selman P, Wolfswinkel J, Mol J. Binding specificity of medroxyprogesterone acetate and proligesterone for the progesterone and glucocorticoid receptor in the dog. Steroids 1996; 61:133-137.
152. Bentel J, Birrell S, Pickering M, et al. Androgen receptor agonist activity of the synthetic progestin medoxyprogesterone acetate, in human breast cancer cells. Mol Cell Endocrinol 1999; 154:11-20.
153. Bamberger C, Else T, Bamberger A, et al. Dissociative glucocorticoid activity of Medroxyprogesterone Acetate in normal human lymphocytes. J Biol Chem 1999; 84:4055-4061.
154. Stockler M, Wilcken N, Ghersi D, et al. Systematic reviews of chemotherapy and endocrine therapy in metastatic breast cancer. Cancer Treatment Rev 2000; 26:151-168.
155. Focan C, Beauduin M, Salamon E, et al. Adjuvant high dose medroxyprogesterone acetate for early breast cancer: 13 years update in a multicentre randomized trial. Br J Cancer 2001; 85:1-8.
156. Hupperets P, Wils J, Volovics L, et al. Adjuvant chemo-hormonal therapy with chclophosphamide, doxorubicin and 5-fluroruacil (CAF) with or without medroxyprogesterone, acetate (MPA) for node-positive cancer patients, update at 12 years follow up. Breast 2001; 10:35-37.